Breaking News

Erdogan Selects Ahmet Davutoglu as Turkey's Next Prime Minister
Tweet TWEET

StemCells, Inc. to Present at 2012 World Stem Cell Summit

StemCells, Inc. to Present at 2012 World Stem Cell Summit

NEWARK, Calif., Nov. 29, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc.
(Nasdaq:STEM) announced today that Ann Tsukamoto, Ph.D., Executive Vice
President, Research and Development, will make a presentation on the Company's
clinical development programs at the 2012 World Stem Cell Summit to be held
December 3-5 at the Palm Beach County Convention Center, West Palm Beach,
Florida. Dr. Tsukamoto is scheduled to speak during the Clinical Trial Update
session to be held 10:30 a.m. to 12:00 p.m. Eastern Time on Tuesday, December
4.Dr. Tsukamoto also will be moderating a discussion on the topic "Unproven
Stem Cell Therapies and Deceptive Claims: Hidden Dangers to Patients."This
plenary discussion is scheduled to be held 9:00 to 10:00 a.m. Eastern Time on
Tuesday, December 4.

StemCells, Inc. is a Silver Sponsor of the 2012 World Stem Cell Summit, which
is planned by and for the global stem cell and regenerative medicine community
and is the largest interdisciplinary stem cell conference.The goal of the
2012 World Stem Cell Summit is to accelerate the discovery and development of
lifesaving cures and therapies by bringing together a range of stakeholders to
establish a supportive environment of regulation, legislation, financing,
reimbursement and patient advocacy. 

StemCells, Inc. will be co-hosting a reception on December 4, prior to the
Summit's Stem Cell Action Awards Dinner. The Stem Cell Action Awards
recognize dedicated individuals and organizations that have made distinguished
contributions to the cause of stem cell research.

About StemCells, Inc.

StemCells, Inc. is engaged in the research, development, and commercialization
of cell-based therapeutics and tools for use in stem cell-based research and
drug discovery. The Company's lead therapeutic product candidate, HuCNS-SC®
cells (purified human neural stem cells), is currently in development as a
potential treatment for a broad range of central nervous system disorders. In
a PhaseI clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal
myelination disorder in children, the Company has shown preliminary evidence
of progressive and durable donor-derived myelination in all four patients
transplanted with HuCNS-SC cells. The Company is also conducting a Phase I/II
clinical trial in chronic spinal cord injury in Switzerland and recently
reported positive interim data for the first patient cohort.The Company has
also initiated a Phase I/II clinical trial in dry age-related macular
degeneration (AMD), and is pursuing preclinical studies in Alzheimer's
disease.StemCells also markets stem cell research products, including media
and reagents, under the SC Proven® brand. Further information about StemCells
is available at http://www.stemcellsinc.com.

The StemCells, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=7014

Apart from statements of historical fact, the text of this press release
constitutes forward-looking statements within the meaning of the U.S.
securities laws, and is subject to the safe harbors created therein.These
statements include, but are not limited to, statements regarding the clinical
development of its HuCNS-SC cells; the Company's ability to commercialize drug
discovery and drug development tools; and the future business operations of
the Company. These forward-looking statements speak only as of the date of
this news release. The Company does not undertake to update any of these
forward-looking statements to reflect events or circumstances that occur after
the date hereof. Such statements reflect management's current views and are
based on certain assumptions that may or may not ultimately prove valid. The
Company's actual results may vary materially from those contemplated in such
forward-looking statements due to risks and uncertainties to which the Company
is subject, including those described under the heading "Risk Factors" in the
Company's Annual Report on Form 10-K for the year ended December 31, 2011
and in its subsequent reports on Forms 10-Q and 8-K.

CONTACT: Rodney Young
         StemCells, Inc.
         Chief Financial Officer
         (510) 456-4128
        
         Ian Stone
         Russo Partners
         (619) 308-6541

company logo
 
Press spacebar to pause and continue. Press esc to stop.